Figure 4. .

Time-dependent efficacy of bevacizumab on inflammatory angiogenesis. Bevacizumab treatment was started from day 2, 4, or 6 after IL-1β implantation in BALB/c mouse corneas. (A) Photomicrographs of bevacizumab- or IgG-treated corneas of BALB/c mice on days 2, 4, 6, 10, and 14 after IL-1β implantation. (B–D) Quantitation of the angiogenic area (B), vessel number (C), or portion of vascular tips (D) on days 4, 6, 10, and 14 after IL-1β implantation and treatment with IgG (black) or bevacizumab from day 2 (gray), day 4 (red), or day 6 (blue) (n = 3–10).